Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ANIX |
---|---|---|
09:32 ET | 715 | 3.4 |
09:34 ET | 100 | 3.415 |
09:57 ET | 1018 | 3.31 |
10:12 ET | 100 | 3.45 |
10:19 ET | 1740 | 3.39 |
10:26 ET | 120 | 3.33 |
10:32 ET | 299 | 3.3372 |
10:33 ET | 200 | 3.385 |
10:39 ET | 600 | 3.43 |
10:42 ET | 100 | 3.41 |
10:48 ET | 1500 | 3.435 |
11:00 ET | 1050 | 3.46 |
11:08 ET | 526 | 3.45 |
11:09 ET | 100 | 3.45 |
11:11 ET | 1589 | 3.5 |
11:31 ET | 768 | 3.43 |
12:05 ET | 200 | 3.47 |
12:56 ET | 508 | 3.45 |
01:21 ET | 400 | 3.455 |
01:39 ET | 100 | 3.455 |
01:44 ET | 100 | 3.456 |
01:46 ET | 100 | 3.442 |
01:48 ET | 102 | 3.442 |
01:55 ET | 100 | 3.44 |
03:23 ET | 500 | 3.45 |
03:25 ET | 200 | 3.44 |
03:36 ET | 240 | 3.4131 |
03:52 ET | 2423 | 3.48 |
03:57 ET | 500 | 3.47 |
03:59 ET | 32912 | 3.48 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Anixa Biosciences Inc | 110.1M | -8.9x | --- |
Checkpoint Therapeutics Inc | 109.4M | -1.6x | --- |
Fibrobiologics Inc | 111.1M | -3.5x | --- |
Leap Therapeutics Inc | 108.7M | -1.4x | --- |
Regulus Therapeutics Inc | 111.9M | -1.4x | --- |
Annovis Bio Inc | 112.8M | -1.9x | --- |
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $110.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.87 |
EPS | $-0.39 |
Book Value | $0.78 |
P/E Ratio | -8.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.